Notably, a randomized, placebo-controlled phase III study of masitinib (which targets multiple kinases, including some that may be downstream of the ERBB/HER receptors) demonstrated slowed rate of functional decline, with acceptable safety, in ALS patients, and prolonged survival by over two years as compared with placebo, provided that treatment started prior to severe impairment of functionality [50]. This evidence concerns the gene EGFR and amyotrophic lateral sclerosis.